Paramita Therapeutics, Inc. (Paramita) is a preclinical-stage biotech company backed by seed funding from the National Science Foundation (NSF) and the National Cancer Institute (NCI). We specialize in developing small molecule Multivalent Drug Conjugates (MDCs), a novel approach to cancer treatment. Our proprietary drug conjugation technology offers a key differentiation: the ability to control the multivalency (2, 4, or 8) of cancer-targeting molecules, optimizing binding to target proteins on cancer cells. Our mission is to revolutionize cancer therapy by replacing traditional chemotherapy with our proprietary MDCs, creating new opportunities for pharmaceutical companies and investors. There are no FDA-approved Small Molecule-Drug Conjugates (SMDCs) yet, though many are in development. All FDA-approved drug conjugates are Antibody-Drug Conjugates (ADCs) which use a large antibody to deliver a cytotoxic drug to a tumor cell, unlike SMDCs which use a smaller molecule to do so. Initially, we are focused on developing first-in-class small molecule MDCs to deliver a triple attack against advanced prostate cancer.